References
Black CM, Stephens C. Systemic sclerosis (scleroderma) and related disorders. In: Maddison PY, Isenberg DA, Woo P, Glass DN (eds.) Oxford textbook of rheumatology Oxford: Oxford University Press; 1993: 771–789.
Goodfield MJD, Orchard MA, Rowell NR. Whole platelet aggregation and coagulation factors in patients with systemic sclerosis. Br J Haematol 1993; 84: 675.
Holland CD, Jayson MIV. Venous blood fibrinolysis and fibronolytic potential in primary Raynaud's phenomenon and systemic sclerosis associated Raynaud's phenomenon. In: Black CM, Mayers AM (eds) Current topics in rheumatology. Progressive systemic sclerosis. New York: Gower; 1985: 267–273.
Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor response to activated protein. C. Proc Natl Acad Sci USA 1993; 90: 1004.
Dahlback B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis 1994; 24: 139.
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581.
Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, Ronde H de, Der Velden PA van, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64.
Halbmayer WM, Haushofer A, Schon R, Fischer M. Influence of lupus anticoagulant on a commercially available kit for APC-resistance. Thromb Haemost 1994; 72: 643.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De Lucia, D., De Blasio, G., Belli, A. et al. High prevalence of activated protein C resistance in patients with systemic sclerosis. Int J Clin Lab Res 25, 226–227 (1995). https://doi.org/10.1007/BF02592703
Issue Date:
DOI: https://doi.org/10.1007/BF02592703